Sekisui Chemical

BOARDWALKTECH EXPANDS COMMERCIAL AGREEMENTS WITH THREE EXISITING CUSTOMERS

Retrieved on: 
Tuesday, January 16, 2024

CUPERTINO, Calif, Jan. 16, 2024 /PRNewswire/ - (TSXV: BWLK) (OTCQB: BWLKF) - Boardwalktech Software Corp. ("Boardwalktech" or the "Company"), a leading digital ledger platform and enterprise software solutions company, is pleased to announce that the Company has expanded commercial agreements with three of its existing customers, with one of these customers, Sekisui Chemical, implementing Boardwalktech's new Unity Central application to enhance its supply chain visibility and data management capabilities.

Key Points: 
  • CUPERTINO, Calif, Jan. 16, 2024 /PRNewswire/ - (TSXV: BWLK) (OTCQB: BWLKF) - Boardwalktech Software Corp. ("Boardwalktech" or the "Company"), a leading digital ledger platform and enterprise software solutions company, is pleased to announce that the Company has expanded commercial agreements with three of its existing customers, with one of these customers, Sekisui Chemical, implementing Boardwalktech's new Unity Central application to enhance its supply chain visibility and data management capabilities.
  • In addition to the newly expanded business relationships, Boardwalk has also executed steps to realign its internal resources with a focus on achieving overall profitability, without compromising sales growth.
  • "We continue to see good initial demand for our Unity Central solution both from existing customers and new customers.
  • Combined with our core Digital Ledger solution, Boardwalk can now offer a holistic solution to customers – whether mission critical data resides in spreadsheets or documents ," said Andrew T. Duncan, CEO of Boardwalktech.

NTT Research and Harvard Collaborate on Cardiovascular Bio Digital Twin

Retrieved on: 
Wednesday, November 16, 2022

NTT Research scientists will work with the Disease Biophysics Group (DBG) at SEAS to engineer a model of the human heart, elucidate fundamental laws of muscular pumps, and apply lessons learned to a cardiovascular (CV) bio digital twin model.

Key Points: 
  • NTT Research scientists will work with the Disease Biophysics Group (DBG) at SEAS to engineer a model of the human heart, elucidate fundamental laws of muscular pumps, and apply lessons learned to a cardiovascular (CV) bio digital twin model.
  • His groups long-term goal of engineering a living, functional heart maps well with our CV bio digital twin initiative.
  • I am honored to be joining the MEI Lab team at NTT Research while continuing complementary work at Harvard, Mr. Ishii said.
  • NTT Research is part of NTT, a global technology and business solutions provider with an annual R&D budget of $3.6 billion.

SEKISUI Aerospace Receives 2021 Top Supplier Award from Spirit AeroSystems

Retrieved on: 
Monday, November 15, 2021

RENTON, Wash., Nov. 15, 2021 /PRNewswire/ --SEKISUI Aerospace, a subsidiary of SEKISUI Chemical, was recently recognized as one of Spirit AeroSystems top 12 suppliers for superior performance at its annual supplier recognition symposium in Wichita, Kansas.

Key Points: 
  • RENTON, Wash., Nov. 15, 2021 /PRNewswire/ --SEKISUI Aerospace, a subsidiary of SEKISUI Chemical, was recently recognized as one of Spirit AeroSystems top 12 suppliers for superior performance at its annual supplier recognition symposium in Wichita, Kansas.
  • Daniele Cagnatel, CEO and President of SEKISUI Aerospace added, "The recognition by Spirit and the receipt of this award is a testament to the hard work and dedication of the SEKISUI team.
  • About SEKISUI Aerospace:SEKISUI Aerospace has been manufacturing and engineering products for the commercial aerospace and defense markets for over 32 years.
  • Headquartered in Renton, Washington, SEKISUI Aerospace has additional facilities located in Sumner, Washington and Orange City, Iowa with a total of 570 employees.

Boardwalktech Reports First Quarter Fiscal 2022 Financial Results

Retrieved on: 
Thursday, August 26, 2021

Cupertino, Calif., Aug. 26, 2021 /PRNewswire/ -(TSXV: BWLK) (OTCQB: BWLKF) Boardwalktech Software Corp. ("Boardwalktech" or the "Company"), a leading digital ledger platform and enterprise software solutions company, is pleased to report its financial results for the three month period ended June 30, 2021.

Key Points: 
  • Cupertino, Calif., Aug. 26, 2021 /PRNewswire/ -(TSXV: BWLK) (OTCQB: BWLKF) Boardwalktech Software Corp. ("Boardwalktech" or the "Company"), a leading digital ledger platform and enterprise software solutions company, is pleased to report its financial results for the three month period ended June 30, 2021.
  • Boardwalktech's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").
  • However, the Company does not anticipate a material reduction from legacy revenue for the remainder of FY22.
  • Boardwalktech has developed a patented Digital Ledger Technology Platform currently used by Fortune 500 companies running mission-critical applications worldwide.

Boardwalktech Expands Sekisui Specialty Chemicals Relationship

Retrieved on: 
Monday, July 26, 2021

This is the second application that has been developed for SSCA, with the initial contract previously announced on April 1st, 2020 .

Key Points: 
  • This is the second application that has been developed for SSCA, with the initial contract previously announced on April 1st, 2020 .
  • Sekisui Specialty Chemicals America, LLCis one of 14 subsidiaries of Sekisui America Corporation, a division of Sekisui Chemical Co. Ltd, and one of the world's leading global chemical companies with Sekisui Specialty Chemicals Europe, and Sekisui Specialty Chemicals Mexico.
  • Boardwalktech has developed a patented Digital Ledger Technology Platform used by Fortune 500 companies running hundreds of live mission-critical applications worldwide.
  • Boardwalktech is headquartered in Cupertino, California with offices in India and operations in North America.

COVID-19 Impacts: Spray Polyurethane Foam Will Accelerate at a CAGR of Over 7% Through 2020-2024 | Demand for Spray PU Foams in Construction Industry to Boost Growth | Technavio

Retrieved on: 
Monday, August 10, 2020

Our spray polyurethane foam report covers the following areas:

Key Points: 
  • Our spray polyurethane foam report covers the following areas:
    This study identifies innovations in polyurethane foams as one of the prime reasons driving the spray polyurethane foam growth during the next few years.
  • We provide a detailed analysis of around 25 vendors operating in the spray polyurethane foam, including some of the vendors such as Armacell International SA, BASF SE, Compagnie de Saint-Gobain SA, Covestro AG, FXI, Huntsman International LLC, LANXESS AG, Nitto Denko Corp., Rogers Corp., and Sekisui Chemical Co. Ltd.
  • Backed with competitive intelligence and benchmarking, our research reports on the Spray Polyurethane Foam are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

Boardwalktech and Sekisui Specialty Chemicals Sign New Licensing Deal

Retrieved on: 
Wednesday, April 1, 2020

SSC chose Boardwalktech so it could more frequently and easily produce and optimize constrained forecasts.

Key Points: 
  • SSC chose Boardwalktech so it could more frequently and easily produce and optimize constrained forecasts.
  • We believe using Boardwalktech's solution will have an immediate and noticeable positive impact on our supply chain processes."
  • Sekisui Specialty Chemicals' primary product is Selvol, a line of high-performance polyvinyl alcohol polymers and copolymers used in paper, adhesive, packaging, construction, personal care, and many other specialty formulations.
  • Sekisui Specialty Chemicals is a subsidiary of the Sekisui Chemical Group, a multibillion-dollar, global company that delivers a wide range of products and services to enrich people's lives.

Sekisui Diagnostics Opens $1.9 Million Bioprocess Innovation Centre

Retrieved on: 
Monday, November 25, 2019

BURLINGTON, Massachusetts, Nov. 25, 2019 /PRNewswire/ --Sekisui Diagnostics' Enzyme business unveiled its new Bioprocess Innovation Centre at its site near Maidstone, Kent, UK.

Key Points: 
  • BURLINGTON, Massachusetts, Nov. 25, 2019 /PRNewswire/ --Sekisui Diagnostics' Enzyme business unveiled its new Bioprocess Innovation Centre at its site near Maidstone, Kent, UK.
  • The new Bioprocess Innovation Centre includes 250m2 of laboratory space and 134m2 of office space, more than doubling its R&D laboratory space to facilitate Process Transfer and Development.
  • "This investment represents our commitment to serve our customers with innovative process development solutions," said Will Stockburn, Sekisui Diagnostics (UK) Ltd.'s General Manager.
  • Sekisui Diagnostics isa global company committed to improving patient's lives by providing innovative medical diagnostics to physicians and laboratories through a global commercial network.

Sekisui Diagnostics Opens $1.9 Million Bioprocess Innovation Centre

Retrieved on: 
Monday, November 25, 2019

BURLINGTON, Mass., Nov. 25, 2019 /PRNewswire/ --Sekisui Diagnostics' Enzyme business unveiled its new Bioprocess Innovation Centre at its site near Maidstone, Kent, UK.

Key Points: 
  • BURLINGTON, Mass., Nov. 25, 2019 /PRNewswire/ --Sekisui Diagnostics' Enzyme business unveiled its new Bioprocess Innovation Centre at its site near Maidstone, Kent, UK.
  • The new Bioprocess Innovation Centre includes 250m2 of laboratory space and 134m2 of office space, more than doubling its R&D laboratory space to facilitate Process Transfer and Development.
  • "This investment represents our commitment to serve our customers with innovative process development solutions," said Will Stockburn, Sekisui Diagnostics (UK) Ltd.'s General Manager.
  • Sekisui Diagnostics isa global company committed to improving patient's lives by providing innovative medical diagnostics to physicians and laboratories through a global commercial network.